Not Just Covid - Diagnostic Production/Licensing21 Apr 2021 14:03
Study confirming that diagnostics in areas outside of Covid are missing affimers in their products. Current CEA diagnostic market is projected to be worth ~£2bn in 2023.
Key excerpts below. Notice Abcam are supplying. Pretty typical I imagine, but warming to see the relationship.
Shamsuddin, S.H., Jayne, D.G., Tomlinson, D.C. et al. Selection and characterisation of Affimers specific for CEA recognition. Sci Rep 11, 744. Jan 2021
Carcinoembryonic antigen (CEA) is the only blood based protein biomarker at present, used for preoperative screening of advanced colorectal cancer (CRC) patients to determine the appropriate curative treatments and post-surveillance screening for tumour recurrence. Current diagnostics for CRC detection have several limitations and development of a highly sensitive, specific and RAPID DIAGNOSTIC device is required. The majority of such devices developed to date are antibody-based and suffer from shortcomings including multimeric binding, cost and difficulties in mass production. To circumvent antibody-derived limitations, the present study focused on the development of Affimer proteins as a novel alternative binding reagent for CEA detection. Here, we describe the selection, from a phage display library, of Affimers specific to CEA protein. Characterization of three anti-CEA Affimers reveal that these bind specifically and selectively to protein epitopes of CEA from cell culture lysate and on fixed cells. Kinetic binding analysis by SPR show that the Affimers bind to CEA with high affinity and within the nM range. Therefore, they have substantial potential for used as novel affinity reagents in diagnostic imaging, targeted CRC therapy, affinity purification and biosensor applications.
The majority of such devices developed to date are antibody-based and suffer from shortcomings including multimeric binding, cost and difficulties in mass production. To circumvent antibody-derived limitations, the present study focused on the development of Affimer proteins as a novel alternative binding reagent for CEA detection.
This is the first report to demonstrate a novel affinity reagent generated against CEA-derived from a highly stable non-immunoglobulin Affimer protein scaffold. The successful results indicate the potential of Affimers to be exploited in diagnostic imaging as molecular probes for imaging CEA expressed by tumours.
CEA was sourced from Abcam and was biotinylated with a fivefold molar excess of EZ-Link NHS-SS-Biotin (Thermo Scientific) for 1 h at 20 °C and then desalted using Zeba Spin Desalting Columns (Thermo Scientific).
Sign In
Follow the stocks
